All the mutations that are fit to die

Emma Gebauer1, Markus A Seeliger1

  • 1Laufer Center for Physical & Quantitative Biology, Department of Pharmacological Sciences, School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.

Cell Chemical Biology
|February 16, 2024
PubMed

Insights

Researchers identified key mutations in Src kinase that confer resistance to ATP-competitive inhibitors. This deep mutational screening reveals a dynamically controlled site crucial for drug resistance in cancer therapies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Src kinase is a critical target for ATP-competitive inhibitors in cancer therapy.
  • Understanding resistance mechanisms is essential for developing effective cancer treatments.

Purpose of the Study:

  • To identify specific residues within the Src kinase catalytic domain that confer resistance to ATP-competitive inhibitors.
  • To uncover the mechanisms underlying inhibitor resistance.

Main Methods:

  • Deep mutational screening of 3,500 single point mutations across the entire Src kinase catalytic domain.
  • Analysis of mutation effects on inhibitor binding and kinase activity.

Main Results:

  • Identification of a dynamically controlled resistance site within the Src kinase catalytic domain.
  • Specific mutations at this site significantly confer resistance to ATP-competitive inhibitors.

Conclusions:

  • The identified resistance site is a key determinant of inhibitor efficacy.
  • Targeting this dynamically controlled site may overcome resistance mechanisms in Src-driven cancers.